Data Integrity as Enterprise Risk: What the 2026 Warning Letter Surge Means for the Boardroom

Data integrity is a critical part of pharmaceutical and biologics manufacturing, affecting regulatory compliance, product quality, patient safety, and business continuity. FDA requirements for manufacturing and laboratory records extend across the full data lifecycle, including how information is created, reviewed, modified, retained, and retrieved. Effective pharmaceutical data integrity programs must address electronic records, computerized system controls, user access, audit trails, investigations, and the ALCOA+ principles used to evaluate the reliability of regulated data.

Recent FDA enforcement activity has placed greater attention on how these controls work in practice, particularly audit trail review, out-of-specification investigations, access management, and the reliability of data generated by contract manufacturers and laboratories. Organizations can reduce data integrity risk by assessing current controls, identifying compliance gaps, strengthening procedures and investigations, validating computerized systems, and establishing clear governance and reporting. A risk-based data integrity program helps protect the reliability of quality decisions while supporting compliance with 21 CFR Parts 210, 211, and 11.

Fill out the form to receive our White Paper.